# Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

> **NCT05772208** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 459 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Nimotuzumab
- **DRUG:** neoadjuvant chemotherapy and CCRT

## Key facts

- **NCT ID:** NCT05772208
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 459 (ESTIMATED)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05772208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05772208, "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05772208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*